These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 19583257)
1. A suite of activity-based probes for human cytochrome P450 enzymes. Wright AT; Song JD; Cravatt BF J Am Chem Soc; 2009 Aug; 131(30):10692-700. PubMed ID: 19583257 [TBL] [Abstract][Full Text] [Related]
2. Chemical proteomic probes for profiling cytochrome p450 activities and drug interactions in vivo. Wright AT; Cravatt BF Chem Biol; 2007 Sep; 14(9):1043-51. PubMed ID: 17884636 [TBL] [Abstract][Full Text] [Related]
3. Pyrethroid activity-based probes for profiling cytochrome P450 activities associated with insecticide interactions. Ismail HM; O'Neill PM; Hong DW; Finn RD; Henderson CJ; Wright AT; Cravatt BF; Hemingway J; Paine MJ Proc Natl Acad Sci U S A; 2013 Dec; 110(49):19766-71. PubMed ID: 24248381 [TBL] [Abstract][Full Text] [Related]
4. Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions. Guengerich FP Chem Res Toxicol; 2017 Jan; 30(1):2-12. PubMed ID: 27472660 [TBL] [Abstract][Full Text] [Related]
5. Sulfenylation of Human Liver and Kidney Microsomal Cytochromes P450 and Other Drug-Metabolizing Enzymes as a Response to Redox Alteration. Albertolle ME; Phan TTN; Pozzi A; Guengerich FP Mol Cell Proteomics; 2018 May; 17(5):889-900. PubMed ID: 29374135 [TBL] [Abstract][Full Text] [Related]
6. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Foroozesh M; Primrose G; Guo Z; Bell LC; Alworth WL; Guengerich FP Chem Res Toxicol; 1997 Jan; 10(1):91-102. PubMed ID: 9074808 [TBL] [Abstract][Full Text] [Related]
7. The human hepatic cytochromes P450 involved in drug metabolism. Wrighton SA; Stevens JC Crit Rev Toxicol; 1992; 22(1):1-21. PubMed ID: 1616599 [TBL] [Abstract][Full Text] [Related]
8. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes. Patten CJ; Smith TJ; Murphy SE; Wang MH; Lee J; Tynes RE; Koch P; Yang CS Arch Biochem Biophys; 1996 Sep; 333(1):127-38. PubMed ID: 8806763 [TBL] [Abstract][Full Text] [Related]
9. Recent Structural Insights into Cytochrome P450 Function. Guengerich FP; Waterman MR; Egli M Trends Pharmacol Sci; 2016 Aug; 37(8):625-640. PubMed ID: 27267697 [TBL] [Abstract][Full Text] [Related]
10. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Forrester LM; Henderson CJ; Glancey MJ; Back DJ; Park BK; Ball SE; Kitteringham NR; McLaren AW; Miles JS; Skett P Biochem J; 1992 Jan; 281 ( Pt 2)(Pt 2):359-68. PubMed ID: 1736885 [TBL] [Abstract][Full Text] [Related]
11. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Knights KM; Rowland A; Miners JO Br J Clin Pharmacol; 2013 Oct; 76(4):587-602. PubMed ID: 23362865 [TBL] [Abstract][Full Text] [Related]
13. A Ligand-Based Drug Design. Discovery of 4-Trifluoromethyl-7,8-pyranocoumarin as a Selective Inhibitor of Human Cytochrome P450 1A2. Liu J; Pham PT; Skripnikova EV; Zheng S; Lovings LJ; Wang Y; Goyal N; Bellow SM; Mensah LM; Chatters AJ; Bratton MR; Wiese TE; Zhao M; Wang G; Foroozesh M J Med Chem; 2015 Aug; 58(16):6481-93. PubMed ID: 26222195 [TBL] [Abstract][Full Text] [Related]
14. Designing better drugs: predicting cytochrome P450 metabolism. de Groot MJ Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528 [TBL] [Abstract][Full Text] [Related]
15. Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters. Rendic S; Guengerich FP Curr Drug Metab; 2020; 21(14):1127-1135. PubMed ID: 33292107 [TBL] [Abstract][Full Text] [Related]
16. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. Masubuchi Y; Horie T Crit Rev Toxicol; 2007 Jun; 37(5):389-412. PubMed ID: 17612953 [TBL] [Abstract][Full Text] [Related]
17. Toward Computational Understanding of Molecular Recognition in the Human Metabolizing Cytochrome P450s. Kontoyianni M; Lacy B Curr Med Chem; 2018; 25(28):3353-3373. PubMed ID: 29484977 [TBL] [Abstract][Full Text] [Related]
18. The structure of microsomal cytochrome P450 2C5: a steroid and drug metabolizing enzyme. Johnson EF; Wester MR; Stout CD Endocr Res; 2002 Nov; 28(4):435-41. PubMed ID: 12530646 [TBL] [Abstract][Full Text] [Related]
19. Hepatic Cytochrome P450 Activity, Abundance, and Expression Throughout Human Development. Sadler NC; Nandhikonda P; Webb-Robertson BJ; Ansong C; Anderson LN; Smith JN; Corley RA; Wright AT Drug Metab Dispos; 2016 Jul; 44(7):984-91. PubMed ID: 27084891 [TBL] [Abstract][Full Text] [Related]
20. Antibodies as a probe in cytochrome P450 research. Shou M; Lu AY Drug Metab Dispos; 2009 May; 37(5):925-31. PubMed ID: 19196844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]